



PCSK9 Inhibitors: New York

PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs work by preventing the PCSK9 protein from destroying a receptor on the liver that clears bad cholesterol. The receptor “lives” longer, clearing more LDL cholesterol for the patient.

PCSK9 inhibitors are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access


A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in New York from August 6, 2015 to July 21, 2016.

Key New York Findings



Rejection Rate:

40%



Total rejections:

1,358



Total appeals:

615

Of health plans that received at least 50 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

New York State Government Employees **81%** | Express Scripts **71%**
HealthNow BCBS **58%** | Fidelis Care NY **53%**

The following had **the lowest rates of rejection:**

Independent Health **23%** | Humana Health Plan **21%**
Aetna US Healthcare **17%** | Epic New York **10%**

The following table details claims data for the New York managed care organizations that received at least 50 claims for PCSK9 inhibitors.

MANAGED CARE ORGANIZATION	Rejection %	Total Claims	Approvals	Rejections	Reversals
New York State Government Employees	81.93%	83	9	68	6
Express Scripts	71.53%	144	40	103	1
HealthNow BCBS	58.21%	67	23	39	5
Fidelis Care NY	53.42%	73	31	39	3
United Health Group	52.06%	461	156	240	65
Healthfirst	49.02%	51	23	25	3
MVP Health Care Preferred Care	43.84%	73	34	32	7
CVS Health	38.34%	373	207	143	23
Excellus Health Plan	35.20%	179	106	63	10
Cigna Healthcare	34.86%	109	60	38	11
EmblemHealth	31.53%	111	67	35	9
Capital District Physicians Health Plan	27.27%	88	57	24	7
Independent Health	23.08%	247	156	57	34
Humana Health Plan	21.69%	189	107	41	41
Aetna US Healthcare	17.18%	489	379	84	26
Epic New York	10.17%	59	50	6	3

Data source: National data supplier; Medicare, Medicaid managed care and commercial plans; August 6, 2015-July 21, 2016.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

